DelveInsight’s Idiopathic Pulmonary Fibrosis market report offers comprehensive coverage of the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2017 to 2030 segmented into 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).
Some of the Key Highlights from the Idiopathic Pulmonary Fibrosis Market Report
According to DelveInsight’s, Idiopathic Pulmonary Fibrosis epidemiology insights, the total prevalent population was estimated to be 230,123 in the 7MM in 2020.
The United States accounted for the highest Idiopathic Pulmonary Fibrosis prevalent population among the 7MM in 2020. Out of which the highest IPF cases were reported in the males as compared to the females.
Among the EU5 countries, the UK has the highest IPF population while France had the lowest in 2020.
Some of the major players in the global Idiopathic Pulmonary Fibrosis treatment market in the late phase of clinical development are FibroGen, Roche, Galapagos NV, MediciNova, Galecto Biotech, and others.
Key pipeline therapies in the Idiopathic Pulmonary Fibrosis market include Pamrevlumab, RG6354, Ziritaxestat, Tipelukast, GB 0139, and several others that are anticipated to enter the IPF market in the upcoming years.
FibroGen is developing Pamrevlumab (also known as FG-3019), a first-in-class, a completely humanized monoclonal antibody that suppresses the function of connective tissue growth factor (CTGF), a key mediator in the advancement of fibrosis and other related disorders. It is also being researched for pancreatic cancer and Duchenne muscular dystrophy (DMD) in Phase II developmental stage.
RG6354 (PRM-151) which is being developed by Roche is a recombinant human serum amyloid P/pentraxin 2 protein (PTX2) that is administered intravenously.
Request for a sample to get complete detail on the disease causes, diagnosis, and treatment @ Treatment for Idiopathic Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis market report also covers current treatment practices/algorithms, Idiopathic Pulmonary Fibrosis market drivers, Idiopathic Pulmonary Fibrosis market barriers, and unmet medical needs in order to curate the best opportunities and assess the market’s underlying potential.
Idiopathic Pulmonary Fibrosis: Overview
Idiopathic Pulmonary Fibrosis (IPF) is one of the most severe forms of interstitial pneumonia, characterized by chronic, progressive fibrosis, an inexorable decline in lung function, progressive respiratory failure, and a high mortality rate. The disorder’s classic symptoms include progressive dyspnea and a nonproductive cough. Typically, pulmonary function tests reveal restrictive impairment and decreased carbon monoxide diffusing capacity.
Idiopathic Pulmonary Fibrosis Epidemiology Segmentation
The Idiopathic Pulmonary Fibrosis report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:
Idiopathic Pulmonary Fibrosis Total Diagnosed Prevalent Cases
Idiopathic Pulmonary Fibrosis Gender-Specific Cases
Idiopathic Pulmonary Fibrosis Age-Specific Cases
Idiopathic Pulmonary Fibrosis Prevalent Population by Severity
Idiopathic Pulmonary Fibrosis Treatment Landscape
Non-pharmacological treatment modalities for Idiopathic Pulmonary Fibrosis include supplemental oxygen therapy, pulmonary rehabilitation, mechanical ventilation, and palliative care services. While the pharmacological treatment options for Idiopathic Pulmonary Fibrosis include Corticosteroids, immunosuppressive/cytotoxic agents (azathioprine, cyclophosphamide), and antifibrotic agents (e.g., colchicine or d-penicillamine) can be used alone or in combination. There are two antifibrotic agents that have been approved for Idiopathic Pulmonary Fibrosis treatment namely Esbriet and Ofev (tyrosine kinase inhibitors).
Idiopathic Pulmonary Fibrosis Market
The Idiopathic Pulmonary Fibrosis market size was found to be USD 2781.75 million in the 7MM in 2017.
The United States accounted for 79.2% of the overall IPF market size among the 7MM in 2017.
Among the EU countries, the UK accounted for the highest IPF market share while France had the lowest IPF market share.
The Idiopathic Pulmonary Fibrosis market size is anticipated to increase due to the launch of the upcoming therapies such as Pamrevlumab, RG6354, Ziritaxestat, and others during the forecast period (2020-30).
Get the detailed analysis of the upcoming therapies @ Idiopathic Pulmonary Fibrosis Drug Market
Idiopathic Pulmonary Fibrosis Pipeline Therapies and Key Companies
Pamrevlumab: FibroGen
RG6354: Roche
Ziritaxestat: Galapagos NV
Tipelukast: MediciNova
GB 0139: Galecto Biotech
Idiopathic Pulmonary Fibrosis Market Drivers
Management of Comorbidities
Regulatory designations
Increase in the Geriatric population
Increased potential IPF therapies in the pipeline
Idiopathic Pulmonary Fibrosis Market Barriers
Unavailability of IPF cure
Poor IPF prognosis
Wait and Watch approach
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2017-30
Idiopathic Pulmonary Fibrosis Key Companies: FibroGen, Roche, Galapagos NV, MediciNova, Galecto Biotech, among others.
Idiopathic Pulmonary Fibrosis Key Pipeline Therapies: Pamrevlumab, RG6354, Ziritaxestat, Tipelukast, GB 0139,and others.
Idiopathic Pulmonary Fibrosis Segmentation: By Geography, By Idiopathic Pulmonary Fibrosis therapies
Analysis: Comparative and conjoint analysis of Idiopathic Pulmonary Fibrosis emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Key Insights
2.
Executive summary
3.
Organizations
4.
Idiopathic Pulmonary Fibrosis (IPF): Market Overview at a Glance
5.
Idiopathic Pulmonary Fibrosis (IPF): Overview at a Glance
6.
Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population
7.
Idiopathic Pulmonary Fibrosis Current Treatment Practices
8.
Idiopathic Pulmonary Fibrosis Unmet Needs
9.
Idiopathic Pulmonary Fibrosis Marketed Drugs
10.
Idiopathic Pulmonary Fibrosis Emerging Therapies
11.
Idiopathic Pulmonary Fibrosis (IPF): 7 Major Market Analysis
12.
Idiopathic Pulmonary Fibrosis Seven Major Market Outlook
13.
Idiopathic Pulmonary Fibrosis United States Market Size
14.
15.
16.
SWOT Analysis
17.
Idiopathic Pulmonary Fibrosis Market Access
18.
Case Study
19.
20.
Appendix
21.
DelveInsight Capabilities
22.
Disclaimer
23.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Related Reports
Interstitial Lung Disease Market
Get a comprehensive analysis of Interstitial Lung Disease pipeline therapies and key companies such as Roche, OncoArendi Pharmaceuticals, aTyr Pharma, Bristol Myers Squibb, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/